These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 26983223)
1. [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine]. Zheng WK; Liu Z; Lei X; Tian R; Zheng R; Li N; Ren JT; Du XX; Shang HC Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3693-6. PubMed ID: 26983223 [TBL] [Abstract][Full Text] [Related]
2. [Enlightenment of adverse reaction monitoring on safety evaluation of traditional Chinese medicines]. Song HB; Du XX; Ren JT; Yang L; Guo XX; Pang Y Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1620-3. PubMed ID: 26281610 [TBL] [Abstract][Full Text] [Related]
3. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice]. Shang HC; Zhang BL; Li YP Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528 [TBL] [Abstract][Full Text] [Related]
4. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring]. Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314 [TBL] [Abstract][Full Text] [Related]
5. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations]. Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845 [TBL] [Abstract][Full Text] [Related]
6. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)]. Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304 [TBL] [Abstract][Full Text] [Related]
7. [Research on distribution of patents' holders for Chinese herbal compounds in treating cardiovascular and cerebrovascular based on cluster analysis]. YANG XJ; XIAO SY Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3682-6. PubMed ID: 26983221 [TBL] [Abstract][Full Text] [Related]
8. [Post-marketing reevaluation for potential quality risk and quality control in clinical application of traditional Chinese medicines]. Li HJ; He LY; Liu BY Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2461-3. PubMed ID: 26591543 [TBL] [Abstract][Full Text] [Related]
9. To establish a body of evidence on safety for postmarketing Chinese medicine: A new research paradigm. Liao X; Xie YM; Robinson N; Wang YY Chin J Integr Med; 2017 Mar; 23(3):226-232. PubMed ID: 27900605 [TBL] [Abstract][Full Text] [Related]
10. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection. Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892 [TBL] [Abstract][Full Text] [Related]
11. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world]. Yang W; Xie Y; Zhuang Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363 [TBL] [Abstract][Full Text] [Related]
12. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine]. Yan BH; Peng C; Xie YM; Wang YY Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315 [TBL] [Abstract][Full Text] [Related]
13. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)]. Xie YM; Wang X; Wang N; Chang YP Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305 [TBL] [Abstract][Full Text] [Related]
14. [Post-marketing clinical study of traditional Chinese medicine--lessons learned from comprehensive evaluation of Fufang Zaoren capsule]. Qing S; Gao L; Zhang L; Jia JP; Liu XM; Ji SL; Yang XH Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(21):3790-4. PubMed ID: 24494575 [TBL] [Abstract][Full Text] [Related]
15. [Core elements of safety monitoring report of medicines(Chinese patent medicines)]. Wang GQ; Liao X; Xie YM Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4483-4487. PubMed ID: 28936827 [TBL] [Abstract][Full Text] [Related]
16. [Dynamic monitoring risk of anti-hepatoma new drug development]. Zhang J; Fan W; Li HF; Man SL; Liu Z; Gao WY Zhongguo Zhong Yao Za Zhi; 2014 Oct; 39(20):4050-3. PubMed ID: 25751961 [TBL] [Abstract][Full Text] [Related]
17. [Significance of re-evaluation and development of Chinese herbal drugs]. Gao Y; Ma Z; Zhang B Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(1):1-4. PubMed ID: 22741451 [TBL] [Abstract][Full Text] [Related]
18. [Survey on Xiaoke pill treating diabetes mellitus in small cities' Chinese medicine hospital for post-marketing surveillance]. Xie Y; Zhao Y; Liu H; Wang Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2859-61. PubMed ID: 22292385 [TBL] [Abstract][Full Text] [Related]
19. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance]. Zhang W; Xie YM; Yu WY Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309 [TBL] [Abstract][Full Text] [Related]
20. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici). Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]